Abstract
Purpose: To incorporate quality-of-life considerations in assessing high dose therapy (HDT) for patients with Multiple Myeloma (MM). Patients and methods: A quality-adjusted survival analysis, using the quality-adjusted time without symptoms or toxicity (Q-TWiST) method, was applied to two randomized clinical trials conducted in patients with MM which compared randomized assignment to HDT vs. conventional chemotherapy (CCT) alone (MAG91) or followed by HDT (MAG90). Treatment benefit in terms of mean Q-TWiST was assessed through threshold utility analyses, i.e., sensitivity analyses of the choice of the utility coefficients over all possible values of utility weights. Results: In both trials, results slightly favored the first-line HDT group over the first-line CCT group, with an average gain in TWiST of about 5.5 months over the 58 month-median follow-up period (27.8 vs. 22.3 months, respectively) in the MAG90 trial and 5.8 months over the 56 month-median follow-up period (19.1 vs. 13.3 months, respectively) in the MAG91 trial. The utility threshold analyses revealed that the first-line HDT group had a statistically increased mean quality-of-life adjusted time compared to the other group for a broad range of utility coefficient values. Conclusion: The development of such understandable and intuitive measures of expressing the relative benefit of complex treatment strategies is expected to be used in clinical decision making in the near future.
Similar content being viewed by others
References
Attal M, Harousseau JL, Stoppa AM, et al. A Prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in Multiple Myeloma. N Engl J Med 1996; 335(2): 91–97.
Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92(9): 3131–3136.
Fermand JP, Ravaud P, Katsahian S, et al. High-dose therapy (HDT) and autologous blood stem cell (ABSC) transplantation vs. conventional treatment in multiple myeloma (MM): Results of a randomized trial in 190 patients 55–65 years of age. Blood 1999; 94(10, Suppl 1): 402a.
Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med 1990; 9(11): 1259–1276.
Gelber RD, Cole BF, Gelber S, Goldhirsch A. Comparing treatments using quality-adjusted survival: The Q-TWiST method. Am Stat 1995; 49: 161–169.
Gelber RD, Goldhirsch A, Cole BF, Wieand HS, Schroeder G, Krook JE. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst 1996; 88(15): 1039–1045.
Trippoli S, Becagli P, Messori A. Adjuvant cyclophosphamide, methotrexate and fluorouracil for node-positive breast cancer: A lifetime cost-utility analysis based on a modified Q-TWIST method. Eur J Clin Pharmacol 1997; 53(3–4): 281–282.
Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of interferon a-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 1996; 14(10): 2666–2673.
Agarwala SS, Kirkwood JM. Adjuvant interferon treatment for melanoma. Hematol Oncol Clin North Am 1998; 12(4): 823–833.
DeCosse JJ, Cennerazzo WJ. Re: A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst 1996; 88(22): 1686.
Pummer K, Lehnert M, Stettner H, Hubmer G. Randomized comparison of total androgen blockade alone vs. combined with weekly epirubicin in advanced prostate cancer. Eur Urol 1997; 32(Suppl 3): 81–85.
Rosendahl I, Kiebert GM, Curran D, et al. Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: Comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer. Prostate 1999; 38(2): 100–109.
Cole BF, Solal-Celigny P, Gelber RD, et al. Quality-of-lifeadjusted survival analysis of interferon a-2b treatment for advanced follicular lymphoma: An aid to clinical decision making. J Clin Oncol 1998; 16(7): 2339–2344.
Parsons SK, Gelber S, Cole BF, et al. Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: A Q-TWiST analysis of the pediatric oncology group study 8821. J Clin Oncol 1999; 17(7): 2144–2152.
Zee B, Cole B, Li T, et al. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol 1998; 16(8): 2834–2839.
Schwartz CE, Mathias SD, Pasta DJ, et al. A comparison of two approaches for assessing patient importance weights to conduct an Extended Q-TWiST analysis. Qual Life Res 1999; 8(3): 197–207.
Elwyn G, Edwards A, Gwyn R, Grol R. Towards a feasible model for shared decision making: Focus group study with general practice registrars. Br Med J 1999; 319(7212): 753–756.
Charles C, Whelan T, Gafni A. What do we mean by partnership in making decisions about treatment? Br. Med J 1999; 319(7212): 780–782.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Porcher, R., Lévy, V., Fermand, J. et al. Evaluating high dose therapy in Multiple Myeloma: Use of quality-adjusted survival analysis. Qual Life Res 11, 91–99 (2002). https://doi.org/10.1023/A:1015096313594
Issue Date:
DOI: https://doi.org/10.1023/A:1015096313594